



Translated from *Rev Prescrire* June 2010; 30 (320): 432

## Tibolone and breast cancer

● **Tibolone** is a synthetic steroid marketed for the treatment of menopausal symptoms.

● A cohort study of women with no history of breast cancer showed that **tibolone** was associated with an increased risk of breast cancer.

● In women with a history of breast cancer, a placebo-controlled trial showed a higher risk of breast cancer recurrence with **tibolone**.

● A placebo-controlled trial of half the standard dose of **tibolone** showed no increased risk of breast cancer but was interrupted due to an increased risk of stroke.

● In practice, it is better simply not to use **tibolone**.

*Rev Prescrire* 2010; 30 (320): 432.

**T**ibolone is a synthetic steroid with oestrogenic, progestogenic and androgenic properties. It is marketed for symptomatic relief of menopausal symptoms (1-3).

In the Women's Health Initiative (WHI), a randomised double-blind trial including 16 000 postmenopausal women with a mean age of 63 years at enrolment and who were monitored for 5.2 years on average, oestrogen-progestogen treatment was associated with 8 additional invasive breast tumours per 10 000 woman-years compared to placebo (4).

This review examines the latest data on the risk of breast cancer in women treated with **tibolone**.

**Postmenopausal women with no history of breast cancer: increased risk of breast cancer.** The British Million Women Study involved a cohort of postmenopausal women aged 50 to 64 years who were monitored for an average of 2.6 years. Among the women who used hormone replacement therapy, 6% took **tibolone**.

Among women treated with **tibolone**, the risk of being diagnosed with invasive breast cancer was 1.5 times higher than

in women who did not use hormone replacement therapy (relative risk (RR): 1.45; 95% confidence interval (CI): 1.25 to 1.68) (1-5)(a).

**A placebo-controlled trial: increased risk of breast cancer recurrence.** The Liberate study, a randomised double-blind multicentre trial, compared **tibolone** 2.5 mg/day versus placebo in terms of the risk of breast cancer recurrence. It included 3148 women with a mean age of 53 years and a history of surgically treated breast cancer. Most of the women were receiving **tamoxifen**, an oestrogen antagonist.

After a median follow-up of 3.1 years, a statistically significant increase in the rate of breast cancer recurrence was observed in the **tibolone** group (237 cases, versus 165 cases in the placebo group; RR: 1.4; 95% CI 1.1-1.7) (6).

**An uninformative trial of half the standard dose of tibolone.** The Lift study, a randomised double-blind trial, compared **tibolone** versus placebo for fracture prevention in 4538 osteoporotic postmenopausal women aged 60 to 85 years. The daily **tibolone** dose was half that recommended in the marketing authorisation (1.25 mg instead of 2.5 mg) (7).

The trial was interrupted because of an excess of strokes in the **tibolone** group, after a median treatment period of 3 years (RR: 2.19; 95% CI 1.14-4.23;  $p=0.02$ ).

The risk of breast cancer was one of the secondary endpoints. The incidence of invasive breast cancer was lower in the **tibolone** group than in the placebo group, with respectively 6 cases (0.9 per 1000 patient-years) and 19 cases (2.8 per 1000 patient-years) (RR: 0.32; 95% CI: 0.13-0.80;  $p=0.02$ ) (b)(8). These results are not very reassuring, however, given the low dose regimen (c).

**In practice.** **Tibolone** appears to increase the risk of breast cancer in postmenopausal women when used at the standard dose. A trial evaluating a lower dose was stopped because of an increased risk of stroke in the **tibolone**

arm. In summary, the risks associated with **tibolone** outweigh its benefits.

©Prescrire

*a-* A UK case-control study showed no increase in breast cancer in women taking **tibolone**. However, the risk was higher in the subset of women who switched to **tibolone** from oestrogen-progestogen therapy (9).

*b-* This trial was funded by Organon, the company that markets **tibolone** (ref 7).

*c-* By convention, prior definition of a primary endpoint authorises the use of a  $p$  value of  $<0.05$  to define statistical significance, while for secondary endpoints a threshold of 0.01 more closely reflects the 5% error risk (ref 10).

### Selected references from Prescrire's literature search.

1- Prescrire Editorial Staff "Tibolone: cancers of the breast and endometrium" *Prescrire Int* 2006; **15** (83): 107.

2- Prescrire Rédaction "8-2. Patientes ménopausées" *Rev Prescrire* 2009; **29** (314 suppl. interactions médicamenteuses).

3- Prescrire Editorial Staff "Tibolone" *Prescrire Int* 2002; **11** (59): 79-82.

4- Prescrire Editorial Staff "Post-menopausal hormone replacement therapy" *Prescrire Int* 2004; **13** (71): 106-109.

5- Million Women Study Collaborators "Breast cancer and hormone-replacement therapy in the Million Women Study" *Lancet* 2003; **362**: 419-427.

6- Kenemans P et al. "Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial" *Lancet Oncol* 2009; **10**: 135-146.

7- "Livial". In French datasheet compendium: "Dictionnaire Vidal" Vidal, Issy-les-Moulineaux 2010: 1204-1205.

8- Cummings SR et al. "The effects of tibolone in older postmenopausal women" *N Engl J Med* 2008; **359** (7): 697-708.

9- Opatrný L et al. "Hormone replacement therapy use and variations in the risk of breast cancer" *Br J Obstet Gynecol* 2008; **115** (2): 169-175 + (7): 918-919.

10- Prescrire Rédaction "La "valeur p" résume-t-elle la pertinence d'une comparaison?" *Rev Prescrire* 2008; **28** (298): 621-622.